All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Squandering much of what could have been a good opportunity to better understand the pricing of prescription drugs, the U.S. Senate Health, Education, Labor and Pensions (HELP) Committee reverted to political bickering over repeal of the Affordable Care Act (ACA) in the first of a series of three hearings billed as a bipartisan fact-finding into the who, what and why of drug prices.